There was a sharp rise in the share price of Destiny Pharma (LON: DEST) following the results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections. The shares have fallen back, and they remain attractive considering the potential for this antimicrobial treatment.
The study covered 124 patients. Destiny says there was a 99.5% reduction of infection in the nose 24 hours before open heart surgery. XF-73 is also safe and well tolerated. There is no antimicrobial resistance generated.
The next step will be the design of a phase III study...
